Lv4
546 积分 2025-08-28 加入
First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial
4天前
已完结
The next generation of antibody–drug conjugates
17天前
已完结
Clinical toxicity of ADCs and ICI-ADC combinations: mechanisms, patterns and management
20天前
已完结
Response assessment criteria for brain metastases: proposal from the RANO group
23天前
已完结
Multicenter Retrospective Analysis of the Safety and Efficacy of Sacituzumab Govitecan Combined With Radiation Therapy: The French ATTENTION Study
25天前
已关闭
Multicenter Retrospective Analysis of the Safety and Efficacy of Sacituzumab Govitecan Combined with Radiotherapy: The French ATTENTION Study
25天前
已完结
Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study
30天前
已完结
Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study
30天前
已完结
Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework
1个月前
已完结
皖公网安备34019202002308
